Amrita Krishnan, M.D.
Location
Newport Beach
Newport Beach, CA 92660
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, CA 92618
Education & Experience
1990, Albany Medical College, Albany, NY, M.D., Medicine
1988, Union College, Schenectady, NY, B.S., Biology/Modern Languages
1996 - 1997, Clinical Fellow, Bone Marrow Transplantation City of Hope
1993 - 1996, Clinical Fellow, Hematology-oncology Beth Israel Hospital, Harvard University Boston MA
1993 - 1996, Clinical Fellow Clinical Fellow in Medicine, Harvard Medical School Boston MA
1995 - 1996, Research Fellow Division of Hematologic Malignancies, Principal Investigator, J. Ritz Dana Farber Cancer Institute Harvard University, Boston MA
1995, Clinical Fellow, Bone Marrow Transplantation Fred Hutchinson Cancer Research Center, University of Washington Seattle WA
1995, Clinical Fellow, Bone Marrow Transplantation, Solid Tumor and Lymphoma Autologous Marrow Program Dana Farber Cancer Institute and Beth Israel Hospital, Boston, MA
1991 - 1993, Strong Memorial Hospital University of Rochester, Rochester, NY
2022-present, Executive Medical Director, Hematology, City of Hope Orange County
2021-present, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2015-present, Director, Judy and Bernard Briskin Center for Myeloma, City of Hope, Duarte, CA
2004-2018, Associate Director, Medical Education and Training, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
1997-present, Staff Physician, Department of Hematology and Hematopoietic Cell Transplantation City of Hope
Publications
- Dona AA, Sanchez JF, Palmer JM, Synold TW, Chiuppesi F, Thomas S, Caserta E, Singer M, Tandoh T, Chowdhury A, Krishnan A, Rosenzweig M, Diamond DJ, Rosen S, Pichiorri F, Dadwal S. Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes. J Immunol Sci. 2023;7(1):9-27. doi: 10.29245/2578-3009/2023/1.1241. Epub 2023 Jan 20. PMID: 36996290; PMCID: PMC10042490.
- D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol. 2023 Jan;98(1):140-147. doi: 10.1002/ajh.26596. Epub 2022 May 21. PMID: 35567778; PMCID: PMC9659666.
- Tanenbaum HC, Birmann BM, Bertrand KA, Teras LR, Krishnan AY, Pourhassan H, Goldsmith S, Cannavale K, Wang SS, Chao CR. Identifying monoclonal gammopathy of undetermined significance from electronic health records. Cancer Rep (Hoboken). 2023 Mar;6(3):e1755. doi: 10.1002/cnr2.1755. Epub ahead of print. PMID: 36464325.
- Murtadha M, Park M, Zhu Y, Caserta E, Dona AA, Singer M, Vahed H, Tasndoh T, Gonzalez A, Ly K, Sanchez JF, Chowdhury A, Pozhitkov A, Ghoda L, Li L, Zhang B, Krishnan A, Marcucci G, Williams J, Pichiorri F. Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia. bioRxiv [Preprint]. 2023 Mar 1:2023.02.27.530273. doi: 10.1101/2023.02.27.530273. PMID: 36909542; PMCID: PMC10002674.
- Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. Bone Marrow Transplant. 2023 May 6. doi: 10.1038/s41409-023-02004-5. Online ahead of print. PMID: 37149674
- Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, Lin X, Qi K, Londhe A, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Usmani SZ.Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. J Comp Eff Res. 2023 Jun;12(6):e220186. doi: 10.57264/cer-2022-0186. Epub 2023 Apr 28. PMID: 37114426
- Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, Perpinial M, Chen J, He TF, Mansour AG, Teng KY, Bhattacharya S, Caserta E, Troadec E, Lee P, Feng M, Keats J, Krishnan A, Rosenzweig M, Yu J, Caligiuri MA, Cohen Y, Shevetz O, Becker-Herman S, Pichiorri F, Rosen S, Shachar I. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.JCI Insight. 2023 Jul 24;8(14):e173312. doi: 10.1172/jci.insight.173312.PMID: 37485873
- Chari A, Askari E, Caers J, Costa LJ, Hilder BW, Krishnan A, Mateos MV, Minnema MC, Oriol A, Pillarisetti K, van de Donk NWCJ, Rodríguez-Otero P. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma. Future Oncol. 2023 Jul 26. doi: 10.2217/fon-2023-0332. Online ahead of print.PMID: 37492991.
- Sidana S, Moreau P, Garfall A, Bhutani M, Oriol A, Nooka A, Martin T, Rosiñol Dachs L, Mateos MV, Bahlis NJ, Popat R, Besemer B, Martinez-Lopez J, Krishnan A, et. al. P879: Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). HemaSphere. 2023 Aug 8;7(Suppl ):e62475d0. doi: 10.1097/01.HS9.0000970420.62475.d0. PMCID: PMC10431083.
- Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, et. al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31. PMID: 37653344; PMCID: PMC10504087.
- Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, Kobos R, Stephenson T, Kemmerer K, Uhlar CM, Banerjee A, Goldberg JD, Trancucci D, Apte A, Verona R, Pei L, Desai R, Hickey K, Su Y, Ouellet D, Samtani MN, Guo Y, Garfall AL, Krishnan A, Usmani SZ, Zhou H, Girgis S. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1. Target Oncol. 2023 Sep;18(5):667-684. doi: 10.1007/s11523-023-00989-z. Epub 2023 Sep 15. PMID: 37713090; PMCID: PMC10518021.
- Liu, L. and Krishnan, A. (2023) “Talquetamab in multiple myeloma”, Haematologica. Early view Oct 19, 2023 doi: 10.3324/haematol.2023.283931.
- Malek E, Kort J, Metheny L, Fu P, Hari P, Li G, Efebera Y, Callander N, Qazilbash M, Giralt S, Krishnan A, et. al. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Res Sq [Preprint]. 2023 Sep 21:rs.3.rs-3318127. doi: 10.21203/rs.3.rs-3318127/v1. Update in: Transplant Cell Ther. 2024 Jan 18;: PMID: 37790413; PMCID: PMC10543370.
- Rhee JW, Pillai R, He T, Bosworth A, Chen S, Atencio L, Oganesyan A, Peng K, Guzman T, Lukas K, Sigala B, Iukuridze A, Lindenfeld L, Jamal F, Natarajan P, Goldsmith S, Krishnan A. et. Al. Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant. JAMA Cardiol. 2024 Jan 1;9(1):16-24. doi: 10.1001/jamacardio.2023.4105. PMID: 37938837; PMCID: PMC10633387.
- Stevens MM, Kimmerling RJ, Olcum S, Vacha M, LaBella R, Minnah A, Katsis K, Fujii J, Shaheen Z, Sundaresan S, Criscitiello J, Niesvizky R, Raje N, Branagan A, Krishnan A, et al. Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies. JCO Precis Oncol. 2024 Jan;8:e2300349. doi: 10.1200/PO.23.00349. PMID: 38237098; PMCID: PMC10805426.